上海莱士(002252) - 2017 Q4 - 年度业绩预告

Financial Performance Forecast - The net profit attributable to shareholders for 2017 is expected to decline by 39% to 49% compared to the previous year, with an estimated profit of 161.315 million yuan[3]. - The company's previous forecast estimated a net profit change of -15% to 15% for the same period[3]. - The decline in performance is primarily due to the suspension of production at the subsidiary Zhengzhou Laisi for capacity expansion and technical upgrades, impacting revenue[4]. - The implementation of the two-invoice system in the pharmaceutical industry also had a short-term negative effect on the company's 2017 revenue[4]. - Significant reductions in fair value changes and investment income from securities due to stock price fluctuations were major contributors to the performance decline[5]. - The financial data provided is a preliminary estimate by the company's finance department, with final figures to be disclosed in the 2017 annual report[6]. - The company expresses sincere apologies for any inconvenience caused to investors due to the performance forecast revision[6].